Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
Background & Aims. Despite significant success in the treatment of acute lymphoblastic leukemia (ALL) in children, relapses and drug resistance to the standard therapy remain the main cause of treatment failure. The addition of bortezomib to the combination therapy of relapsed ALL to change the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2017-07-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/09/11.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849698666194927616 |
|---|---|
| author | NA Batmanova MA Shervashidze AV Popa LYu Grivtsova IN Serebryakova GL Mentkevich |
| author_facet | NA Batmanova MA Shervashidze AV Popa LYu Grivtsova IN Serebryakova GL Mentkevich |
| author_sort | NA Batmanova |
| collection | DOAJ |
| description | Background & Aims. Despite significant success in the treatment of acute lymphoblastic leukemia (ALL) in children, relapses and drug resistance to the standard therapy remain the main cause of treatment failure. The addition of bortezomib to the combination therapy of relapsed ALL to change the sensitivity of blast cells may be a perspective approach to cure patients. The aim was to evaluate the efficacy and toxicity of the anti-relapse ALL treatment protocols REZ BFM 95/96 without bortezomib and COG AALL07P1 with bortezomib in relapsed and refractory ALL in children.
Materials & Methods. The study included 54 children with a confirmed ALL of various localizations. From 1995 to 2011, ALL REZ BFM 95/96 treatment without bortezomib was administered to 26 patients. From 2011 to 2016, 28 children received COG AALL07P1 combination treatment with bortezomib.
Results. The immediate treatment efficacy significantly higher in patients treated with bortezomib (85.7 % vs 57.6 %) after induction chemotherapy with the ALL REZ BFM 95/96. The analysis of the long-term outcomes (disease-free, event-free, overall survival) showed no significant differences between the groups. The event-free survival of patients with isolated bone marrow relapses for a period of 2 years was 20.3 ± 17.5 %. The tolerability of the program was acceptable, complications developing during myelosuppression were not associated with the administration of bortezomib.
Conclusion. The intensification of induction chemotherapy in recurrent remission according to COG AALL07P1 protocol with the addition of bortezomib allowed to increase the number of complete remissions including MRD negative ones. |
| format | Article |
| id | doaj-art-a952fe21485a42aebc7a0c04cc93d6d7 |
| institution | DOAJ |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2017-07-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-a952fe21485a42aebc7a0c04cc93d6d72025-08-20T03:18:50ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392017-07-0110338138910.21320/2500-2139-2017-10-3-381-389Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in ChildrenNA Batmanova0MA Shervashidze1AV Popa2LYu Grivtsova3IN Serebryakova4GL Mentkevich5NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Background & Aims. Despite significant success in the treatment of acute lymphoblastic leukemia (ALL) in children, relapses and drug resistance to the standard therapy remain the main cause of treatment failure. The addition of bortezomib to the combination therapy of relapsed ALL to change the sensitivity of blast cells may be a perspective approach to cure patients. The aim was to evaluate the efficacy and toxicity of the anti-relapse ALL treatment protocols REZ BFM 95/96 without bortezomib and COG AALL07P1 with bortezomib in relapsed and refractory ALL in children. Materials & Methods. The study included 54 children with a confirmed ALL of various localizations. From 1995 to 2011, ALL REZ BFM 95/96 treatment without bortezomib was administered to 26 patients. From 2011 to 2016, 28 children received COG AALL07P1 combination treatment with bortezomib. Results. The immediate treatment efficacy significantly higher in patients treated with bortezomib (85.7 % vs 57.6 %) after induction chemotherapy with the ALL REZ BFM 95/96. The analysis of the long-term outcomes (disease-free, event-free, overall survival) showed no significant differences between the groups. The event-free survival of patients with isolated bone marrow relapses for a period of 2 years was 20.3 ± 17.5 %. The tolerability of the program was acceptable, complications developing during myelosuppression were not associated with the administration of bortezomib. Conclusion. The intensification of induction chemotherapy in recurrent remission according to COG AALL07P1 protocol with the addition of bortezomib allowed to increase the number of complete remissions including MRD negative ones.http://bloodjournal.ru/wp-content/uploads/2017/09/11.pdfacute lymphoblastic leukemiarefractorinessrelapsesbortezomib |
| spellingShingle | NA Batmanova MA Shervashidze AV Popa LYu Grivtsova IN Serebryakova GL Mentkevich Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children Клиническая онкогематология acute lymphoblastic leukemia refractoriness relapses bortezomib |
| title | Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children |
| title_full | Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children |
| title_fullStr | Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children |
| title_full_unstemmed | Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children |
| title_short | Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children |
| title_sort | bortezomib combination therapy of relapsed and refractory acute lymphoblastic leukemia in children |
| topic | acute lymphoblastic leukemia refractoriness relapses bortezomib |
| url | http://bloodjournal.ru/wp-content/uploads/2017/09/11.pdf |
| work_keys_str_mv | AT nabatmanova bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren AT mashervashidze bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren AT avpopa bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren AT lyugrivtsova bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren AT inserebryakova bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren AT glmentkevich bortezomibcombinationtherapyofrelapsedandrefractoryacutelymphoblasticleukemiainchildren |